Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

Phase 3

Completed

• Conditions: Infections, Meningococcal
• Interventions: Biological: Meningococcal group B Vaccine, rMenB+OMV NZ; Biological: Meningococcal ACWY Conjugate Vaccine, MenACWY

• Registration Number: NCT02106390
• Lead Sponsor: GlaxoSmithKline

Brief Summary

The purpose of this trial is to evaluate the immunogenicity, the safety and the tolerability of rMenB+OMV NZ and MenACWY vaccines in healthy infants, when concomitantly administered at 3, 5, 7 and 13 months of age, compared to either alone.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-02-14
• Study First Submitted QC: 2014-04-03
• Study First Posted: 2014-04-08
• Study Start: 2014-06-05
• Primary Completion: 2016-10-14
• Study Completion: 2016-10-14
• Results First Submitted: 2017-10-06
• Status Verified: 2018-01
• Results First Submitted QC: 2018-06-14
• Last Update Submitted: 2018-06-14
• Results First Posted: 2018-08-22
• Last Update Posted: 2018-08-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 750

Inclusion Criteria

1. Healthy 3-month old infants (85-119 days, inclusive) at time of Visit 1 whose parents/legal guardians have given written informed consent after the nature of the study has been explained.
2. Available for all the visits scheduled in the study.
3. In good health as determined by medical history, physical examination and clinical judgment of the investigator.

Read More

Exclusion Criteria

1. History of any previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s) at the time of enrollment.

2. Previous known or suspected disease caused by N. meningitidis.

3. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection or colonization.

4. History of severe allergic reaction after previous vaccinations, or hypersensitivity to any component of the vaccine.

5. Known or suspected autoimmune disease or impairment/alteration of the immune system resulting from, for ex-ample:

   • Chronic administration of immunosuppressants or other immune-modifying drugs since birth (3 months prior). (For corticosteroids, this means prednisone, or equivalent, ≥ 0.5 mg/kg/day or ≥ 10 mcg/day for children below 2 years. Inhaled and topical steroids are allowed),
   • Immune deficiency disorder, or known HIV infection.

6. Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation since birth.

7. History of any progressive or severe neurologic disorder, or seizure disorder or Guillan Barré syndrome (exception: one self-limited febrile seizure is acceptable).

8. History of any bleeding disorder considered as a contraindication to intramuscular injection or blood draw.

9. Child's parent(s) or legal guardian(s) are not able to comprehend and to follow all required study procedures for the whole period of the study.

10. Receipt of any investigational or non-registered product since birth (3 month prior) or are expected to receive during the study period.

11. Family members or household members of site research staff.

12. Any clinically-significant chronic or progressive disease according to judgment of the investigator (pulmonary, cardiovascular, renal, hepatic or endocrine functional abnormality) or a congenital anomaly/known cytogenic disorder (e.g., Down's syndrome).

13. History or any illness/condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
rMenB+ACWY	Meningococcal ACWY Conjugate Vaccine, MenACWY	Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
rMenB+ACWY	Meningococcal group B Vaccine, rMenB+OMV NZ	Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
MenACWY	Meningococcal ACWY Conjugate Vaccine, MenACWY	Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
rMENB	Meningococcal group B Vaccine, rMenB+OMV NZ	Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.

Primary Outcome Measures

Name	Time	Method
Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against Each of the Serogroup B Indicator Strains	At Day 331 (one month after the fourth vaccination)	Human serum bactericidal activity (hSBA) titers against each of the serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 after receiving 4 doses of rMenB+OMV NZ / MenACWY vaccines, concomitantly administered, versus corresponding response in subjects who received rMenB+OMV NZ administered alone, were presented in terms of vaccine group specific geometric mean titers (GMTs).; This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
hSBA Geometric Mean Titers (GMTs) Against Each of the Serogroups A, C, W-135 and Y	At Day 331 (one month after the fourth vaccination)	hSBA titers against N. meningitidis serogroups A, C, W-135 and Y after receiving four doses of either rMenB+OMV NZ / MenACWY concomitantly administered versus corresponding response in subjects who received MenACWY administered alone were presented in terms of vaccine group specific GMTs.; This outcome measure applies to only rMenB+ACWY and MenACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.

Secondary Outcome Measures

Name	Time	Method
Number of Subjects With Solicited Local and Systemic Adverse Events (AEs)	From Day 1 (6 hours) to Day 7 after each vaccination (Days 1, 61, 121 and 301)	Number of subjects with solicited local and systemic AEs during the 7 days (including the day of vaccination) after any vaccination
hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.	At Day 331 (one month after the fourth vaccination)	hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331).; This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
hSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.	At Day 331 (one month after the fourth vaccination)	hSBA GMTs against each of the N.meningitidis serogroups A, C, W-135, Y at one month after the fourth vaccination (Day 331).; This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.
hSBA Geometric Mean Titers Against Each of the Serogroups A, C, W-135 and Y	At Day 151 (one month after the third vaccination)	hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y at one month after the third vaccination (Day 151).; This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.
Number of Subjects With Unsolicited Adverse Events	From Day 1 to Day 7 after each vaccination (Days 1, 61, 121 and 301)	An unsolicited adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.
Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Indicator Strains	At Day 151 (one month after the third vaccination)	Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 one month after the third vaccination (Day 151).; This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Strains.	At Day 331 (One month after the fourth vaccination)	Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 one month after the fourth vaccination (Day 331).; This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
Percentage of Subjects With hSBA Titers ≥1:4 Against Each of the Serogroups A, C, W-135 and Y	At Day 1	Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y before the first vaccination (Day 1).; This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
Within-subject Geometric Mean Ratios (GMRs) Against Each of the Serogroup B Indicator Strains	At Day 331 (one month after fourth vaccination)	Geometric Mean Ratios(GMRs) of GMTs against each of the serogroup B indicator strains- H44/76, 5/99, N98/254 \& M10713 were calculated at one month after the fourth vaccination (Day 331) versus pre fourth vaccination(Day 301).
Within-subject Geometric Mean Ratios (GMRs) Against Each of Serogroups A, C, W-135 and Y	At Day 331 (one month after the fourth vaccination)	Geometric Mean Ratios(GMRs) of GMTs against each of the serogroups A,C,W-135 \& Y were calculated at one month after the fourth vaccination (Day 331) versus pre fourth vaccination (Day 301).
Percentage of Subjects With Four-fold Increases in hSBA Titers Against Each of the Serogroups A, C, W-135 and Y	At Day 331 (one month after the fourth vaccination)	Percentages of subjects with four-fold increases in hSBA against each of the N. meningitidis serogroups A,C,W \& Y at one month after the fourth vaccination (Day 331) over pre-fourth vaccination(Day 301).; This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.; For serogroups A, C, W and Y, 4-fold increase in titers was defined as post 4th vaccination titer ≥16 (if pre 4th vaccination titer was \<4) or post 4th vaccination titer ≥ 4 x pre 4th vaccination titer (if pre 4th vaccination titer was ≥4).
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y	At Day 331 (one month after the fourth vaccination)	Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 \& Y at one month after the fourth vaccination (Day 331).; This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
Percentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains	At Day 301 (before the fourth vaccination)	Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains before the fourth vaccination (Day 301).; This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroup B Indicator Strains	At Day 331 (one month after the fourth vaccination)	Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331).; This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
Percentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y	At Day 331 (one month after the fourth vaccination)	Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
Percentage of Subjects With Four-fold Increases in hSBA Titers Against Each of the Serogroup B Indicator Strains	At Day 331 (one month after the fourth vaccination)	Percentage of subjects with four-fold increase in hSBA titers against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331) over pre-fourth vaccination (Day 301).; This outcome measure applies to only groups rMenB+ACWY and rMenB as the serogroup B indicator strains were assessed only for these two groups.; For serogroup B strains, 4-fold increase in titers was defined as post 4th vaccination titer ≥8 (if pre 4th vaccination titer was \<2) or post 4th vaccination titer ≥ 4 x pre 4th vaccination titer (if pre 4th vaccination titer was ≥2).
Number of Subjects With SAEs, AEs Leading to Withdrawal and Medically Attended AEs (MAEs)	Throughout the whole study period (from Day 1 upto Day 331)	A serious adverse event is any untoward medical occurrence that at any dose results in death/ is life threatening/requires prolonged hospitalization/Persistent or significant disability/incapacity/congenital anomaly/or birth defect.

Trial Locations

Locations (1)

GSK Investigational Site; 🇲🇽 Morelia, Mexico